A Case of Severe Sprue-like Enteropathy Associated With Olmesartan

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks

    Embargo Policy

    All research presented at the ACG Annual Scientific Meeting is strictly embargoed until 8:00 a.m. on the first day of the Annual Meeting. For 2014, this is Monday, October 20 at 8:00 a.m. EDT.


     

    Poster 1427: A Case of Severe Sprue-like Enteropathy Associated With Olmesartan

    Poster Presentation: Tuesday, Oct 21, 10:30 AM – 4:00 PM

    Juan Corral, MD

    Juan E. Corral, MD

    Author Insight from Juan E. Corral, MD, and Daniel A. Sussman, University of Miami

    What’s new here and important for clinicians?
    Sprue-like enteropathy secondary to olmesartan is a poorly recognized clinical entity. This diagnosis should be considered in patients with signs/symptoms of celiac sprue, but with normal celiac serologies and lack of response to gluten-free diet. Steroids ameliorate symptoms in most cases. Azathioprine and prednisone offered clinical relief but did not restore histological changes. Removal of the offending agent, olmesartan, should be curative.

    What do patients need to know?

    Daniel Sussman, MD

    Daniel A. Sussman, MD

    Olmesartan, a medication use to treat high blood pressure, can induce inflammatory changes in the small intestine that are challenging to distinguish from celiac disease. Common symptoms/signs include diarrhea, vomiting, anemia and low protein levels in the blood.

    Patients who are taking olmesartan and experiencing such symptoms should seek the care of their primary care provider or a gastroenterologist to discuss whether sprue-like enteropathy secondary to olmesartan is a consideration.

    Read the Abstract

    Slide 2009 on Olmesartan

    Slide 2009 on Olmesartan

    Slide 2014 without Olmesartan

    Slide 2014 without Olmesartan

    Author Contact

    Juan E. Corral, MD and Daniel A. Sussman, MD, University of Miami

    je.corral@med.miami.edu

    Related Abstracts

    P212 Olmesartan-Associated Spruelike Enteropathy
    P808 Olmesartan-Induced Spruelike Enteropathy in the Community Setting
    P1433 Olmesartan-Associated Sprue-Like Enteropathy
    P1434 Not All Diarrhea and Villous Atrophy Is Celiac Disease: A Case Report on Olmesartan-Induced Enteropathy


     

    Media Interview Requests:

    Press room and video recording facilities will be available onsite. To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000. From Sunday, October 19 – Wednesday, October 22, in ACG Press Room (Room 119A; Phone 215- 418-2358) at the Pennsylvania Convention Center in Philadelphia.

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks